SPRO (Spero Therapeutics) Operating Income: $14.18 Mil (TTM As of Mar. 2026)

What is Spero Therapeutics Operating Income?

Spero Therapeutics SPRO 55 Operating Income is $14.18 Mil as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spero Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-7.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $14.18 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Spero Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-7.54 Mil. Spero Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.26 Mil. Therefore, Spero Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was -2,921.71%.

Spero Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Spero Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -237.64%. Spero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,204.09%.

Spero Therapeutics (NAS:SPRO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Spero Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-30.152 * ( 1 - 0% )	/	( (22	+	3.376)	/ 2 )
=	-30.152	/	12.688
=	-237.64 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	68.919	-	6.654	-	( 40.265	-	max(0, 8.868	-	67.286	+	40.265	))
=	22

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	59.021	-	3.522	-	( 56.129	-	max(0, 5.489	-	57.612	+	56.129	))
=	3.376

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Spero Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-30.152	/	( ( (1.48 + max(-5.278, 0))	+	(1.256 + max(-2.083, 0)) )	/	2 )
=	-30.152	/	( ( 1.48	+	1.256 )	/	2 )
=	-30.152	/	1.368
=	-2,204.09 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.634)	-	(6.654	+	0.258	+	1.7763568394003E-15)
=	-5.278

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.439)	-	(3.522	+	0	+	0)
=	-2.083

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Spero Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-7.538	/	0.258
	=	-2,921.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Spero Therapeutics Operating Income Related Terms

Spero Therapeutics Operating Income Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Operating Income can be seen below:

Spero Therapeutics Operating Income Chart

Spero Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Operating Income

Get a 7-Day Free Trial

-87.97

-30.57

26.79

-72.48

7.16

Spero Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Operating Income	Get a 7-Day Free Trial															-14.56	-2.36	-7.33	31.41	-7.54

55GF Score

Spero Therapeutics Inc SPRO

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Spero Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.18 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of $14.18 Mil mean?

Spero Therapeutics (SPRO) has a Operating Income of $14.18 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Spero Therapeutics and its competitors.

Is Spero Therapeutics' Operating Income too high?

Spero Therapeutics' current Operating Income is $14.18 Mil. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Spero Therapeutics' Operating Income compare to VXRT and ADCT?

Spero Therapeutics' Operating Income of $14.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Biotechnology company?

A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Operating Income is $14.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Spero Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.27 — trading 114.2% above its estimated fair value. The current Operating Income is $14.18 Mil. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Operating Income is $14.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.27 is trading 114.2% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

Operating Income: $14.18 Mil
GF Value™: $1.06 vs. price of $2.27 (114.2% above fair value)
GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies VXRT ADCT GNLX COYA AGEN VTVT LIXT SMNR CNTB ENLV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 2HA:Germany

Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

55GF Score

Get the complete analysis for SPRO

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.27

Price

$1.06

GF Value

View SPRO Analysis

See Operating Income data for all stocks →